Lyell Immunopharma (LYEL) Enterprise Value: 2019-2025
Historic Enterprise Value for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -$7.6 million.
- Lyell Immunopharma's Enterprise Value rose 91.25% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$956.1 million, marking a year-over-year increase of 42.08%. This contributed to the annual value of -$191.8 million for FY2024, which is 209.36% down from last year.
- Lyell Immunopharma's Enterprise Value amounted to -$7.6 million in Q3 2025, which was up 94.78% from -$146.3 million recorded in Q2 2025.
- Lyell Immunopharma's Enterprise Value's 5-year high stood at $2.9 billion during Q3 2021, with a 5-year trough of -$244.4 million in Q1 2021.
- For the 3-year period, Lyell Immunopharma's Enterprise Value averaged around -$47.4 million, with its median value being -$87.3 million (2024).
- As far as peak fluctuations go, Lyell Immunopharma's Enterprise Value soared by 2,268.00% in 2021, and later slumped by 452.91% in 2025.
- Over the past 5 years, Lyell Immunopharma's Enterprise Value (Quarterly) stood at $1.2 billion in 2021, then crashed by 81.95% to $225.0 million in 2022, then decreased by 22.04% to $175.4 million in 2023, then tumbled by 209.36% to -$191.8 million in 2024, then soared by 91.25% to -$7.6 million in 2025.
- Its Enterprise Value was -$7.6 million in Q3 2025, compared to -$146.3 million in Q2 2025 and -$142.3 million in Q1 2025.